Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell; Sector opened up and slid to the downside at the close

December 19, 2017 5:16pm

As I had stated, “a nervous sector with the lack of news shouting tax loss selling season.

As the NASDAQ (-30.91) and IBB (-0.24%) get whacked

Who says there isn’t a Santa Clause, he delivers in December’s financings: BLUE, VSTM, FATE, VCEL ($25 M of debt), VTGN along with the Ponzi’s and pyramid’s schemes, BSTG with NWBO A and B convertibles

Out and about: The FDA has approved Luxturna; a new gene therapy developed Spark Therapeutics (ONCE) to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna becomes the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.

Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

Henry’omics:

From the pre-open’s newsletter, “…a nervous sector with the lack of news, there seems an over-emphasis on ETF exposure; add in some algorithms mixed with some dark pools and they will suck any value out of share pricing. The problem is, investors don’t get a “buzz” on high frequency trading in the battle for fractions of a cent but, they do usually get screwed!”

It's a "whacky" week ... patience should be a by-word - let is end, go away happy to enjoy and start a holiday.

What do some hope to see, a dramatic rise of a stock with low volume that will burn-out in a nano-second.

Having taken your gains, experienced your losses - walk away to a better NEW Year!

The advance/decline line scenario of 40 SCGT & RT covered companies:

· The open was positive with an A/DL of 20/17 and 3 flat ;

· The mid-day was neutral with an A/DL of 18/18 and 4 flats;

· The close was negative with an A/DL of 17/20 and 3 flat;

MY working trend lines or indications:

… The greatest volume to the downside: IMUC, NWBO, ONCE, RENE.L and XON

… Upside volume was weighted to: JUNO, MDXG, ONVO, ATHX and VTGN

… Biggest $ downside: BLUE (-$2.25), MESO (-$9.60), STML (-$0.55), XON m (-$0.36) and BLFS (-$0.13)

… Largest $ upside: QURE (+$1.01), RGNX (+$0.55), AXGN (+$0.50), BLCM (+$0.26) and VCEL (+0.15)

… Flat: AST, OSIR and VSTM

Out and about:

Spark Therapeutics (ONCE) announced that the FDA has approved LUXTURNA(TM) (voretigene neparvovec-rzyl); a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. LUXTURNA should only be administered to patients with mutations on both copies of the RPE65 gene who have sufficient viable retinal cells as determined by their treating physicians.

LUXTURNA is first gene therapy for a genetic disease, first and only pharmacologic treatment for an inherited retinal disease (IRD) and first adeno-associated virus (AAV) vector gene therapy approved in U.S.

Children and adults living with IRD caused by biallelic RPE65 gene mutations nearly all progress to complete blindness

ONCE will offer comprehensive patient support services for eligible patients in U.S.; will share details on access and price in early January

Daily analytics:

U.S. stock-market indexes closed slightly lower Tuesday as the House of Representatives, as expected, passed a bill that would deliver sweeping corporate tax cuts, sending it to the Senate.

· The Dow slipped 37.45 points, or 0.2%, to 24,754.75, after hitting an all-time high earlier, at 24,876.07 shortly after the opening bell.

· The S&P 500 fell 8.69 points, or 0.3%, to 2,681.47, with eight of the 11 main sectors finishing in negative territory.

· The NASDAQ declined 30.91 points, or 0.4%, to 6,963.85.

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Tuesday traded at 10.03, up +5.255 …

Monday traded at 9.53, up +1.17% after Friday traded at 9.39, down -10.49% after Thursday traded at 10.49, up +3.05% after Wednesday traded at 10.18, up +2.62% and last Tuesday traded at 9.92, up +6.21% …

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

· Tuesday was down -0.76%

· Monday +1.35%

· Friday +1.41%

· Thursday -1.10%

· Wednesday +0.58%

· Last Tuesday -0.31%

… The iShares NASDAQ Biotechnology (IBB) indicated:

· Tuesday was down -0.24%

· Monday -0.23%

· Friday +1.36%

· Thursday -1.45%

· Wednesday +0.91%

· Last Tuesday -0.44%

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

· Tuesday’s decliners ranged from -0.11% <CLLS -$0.03> to -% <NWBO -$0.0423> in 20 equities;

· Monday’s decliners ranged from -1.04% <QURE -$0.18> to -7.95% <BSTG -$0.0063> in 17 equities;

· Friday’s decliners ranged from -0.30% <NWBO -$0.0008> to -18.09% <IMUC -$0.079> in 19 equities;

· Thursday’s decliners ranged from -0.30% <BLUE -$0.55> to -8.60% <FATE -$0.40> in 24 equities;

· Wednesday’s decliners ranged from -0.69% <AGTC -$0.025> to -3.88% <CYTX -$0.0097> in 8 equities;

· Last Tuesday’s decliners ranged from -0.91% <IMUC -$0.0021> to -5.38% <BLUE -$10.85> in 27 equities;

Versus

… Look at the percentage’s (%) and spreads …

· Tuesday’s gainers ranged from +0.18% <JUNO +$0.08> to +5.88% <QURE +$1.01> in 17 equities

· Monday’s gainers ranged from +0.64% <VSTM +$0.02> to +15.33% <MESO +$0.84> in 21 equities

· Friday’s gainers ranged from +0.22% <BTX +$0.01> to +43.27% <BSTG +$0.024> in 19 equities

· Thursday’s gainers ranged from +0.92% <QURE +$0.16> to +82.44% <IMUC +0.182> in 13 equities;

· Wednesday’s gainers ranged from +0.26% <BCLI +$0.01> to +14.21% <CUR +$0.26> in 30 equities;

· Last Tuesday’s gainers ranged from +0.76% <CYTX +$0.00> to +5.15% <MDXG +$0.60> in 11 equities;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.